Checkpoint immunotherapy is largely ineffective in pancreatic ductal adenocarcinoma (PDAC). The innate immune NF-κB pathway promotes PDAC cell survival, stromal fibrosis and is driven by IRAK4, but its impact on tumor immunity has not been directly investigated.